VPT Ventripoint Diagnostics Ltd

Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that
following the clearance by the US Food and Drug Administration (FDA) of the
VMS(TM) heart analysis system for right ventricle assessment in adult patients
with Pulmonary Arterial Hypertension (PAH), the Company has focused on initial
marketing strategies which include: 




--  Securing distribution partners for the VMS(TM) product in the United
    States, 
--  Signing up additional marketing partners in Europe and the Middle East, 
--  Furthering discussions with select leading ultrasound manufacturers for
    collaborations on technology integration, 
--  Licensing the knowledge-based reconstruction to other providers of
    analysis software for other imaging modalities, 
--  Contacting cardiology centers that previously indicated a desire to
    purchase the VMS following clearance for clinical use by the FDA, 
--  Advancing hospital-sponsored clinical studies into new applications for
    the VMS(TM), and 
--  Re-evaluating marketplace acceptance of a pay-per-use structure in
    patients with left heart failure, while maintaining the current capital
    purchase approach in Pulmonary Hypertension and Congenital Heart Disease
    applications.



"Clearance from the FDA has sparked renewed interest in the VMS(TM) in the
cardiology community worldwide. We are seeing accelerated purchase decisions in
Europe and Canada," said Dr. George Adams, President and CEO of Ventripoint.
"Now functional evaluation of the right ventricle is available without an
expensive MRI. We are initiating energetic marketing strategies to communicate
news of the accessibility of VMS(TM). With this in mind, we are making
arrangements to make ourselves very visible at the upcoming meeting of the
American Society of Echocardiography in June."


The Company is also announcing that Don Black has resigned as a Director of the
Company for health reasons. The Board of Directors wishes Don a rapid recovery.
We extend our thanks to Don for his years of service to the Company. The
Nomination Committee has identified a number of possible directors and is
undertaking interviews to find the best replacement.


Furthermore, the Board of Directors of the Company has elected not to initiate a
share consolidation at this time, due to market conditions. The Company is also
negotiating to re-structure some of the secured debt to extend the term.


The VMS(TM) is approved for multiple clinical uses in Canada and Europe, and now
for PAH patients in the United States.


About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading
cause of death in developed countries. VMS(TM) is the first cost-effective and
accurate tool for measuring right ventricle heart function. The Company has a
suite of applications for all major heart diseases and imaging modalities
including congenital heart disease, left or right heart failure and normal
hearts - a multi-billion dollar market potential.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release


FORWARD-LOOKING STATEMENTS: The statements made in this news release that are
not historical facts may contain forward-looking information that involves risk
and uncertainties. All statements, other than statements of historical facts,
which address Ventripoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Company's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. A
description of assumptions used to develop such forward-looking information and
a description of risk factors that may cause actual results to differ materially
from forward-looking information can be found in Ventripoint's disclosure
documents on the SEDAR website at www.sedar.com. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Ventripoint Diagnostics Ltd.
Dr. George Adams
CEO
(206) 910-9125
gadams@ventripoint.com

Ventripoint Diagnostics (TSXV:VPT)
Historical Stock Chart
From Jan 2025 to Feb 2025

Ventripoint Diagnostics (TSXV:VPT)
Historical Stock Chart
From Feb 2024 to Feb 2025